At the same time, it can treat experimental NASH by inhibiting fat synthesis [down‐regulating SREBP‐1, fatty acid synthase (FAS), and acetyl‐CoA carboxylase (ACC)], promoting fat acid oxidation (up‐regulation of CPT‐1 and ACO) (Alberdi et al. 2013; Gomez‐Zorita et al. 2012), and regulating intestinal microflora (Heeboll et al. 2015; Lagouge et al. 2006; Shang et al. 2008); (Salamone et al. 2012) and (Zhang et al. 2013) confirmed that silymarin can inhibit the activity of nuclear factor‐κB (NF‐κB) and regulate IRS‐1/PI3K/AKT pathway to alleviate IR. Here, AKT1 is linked to metabolic dysfunction-associated steatohepatitis.